150 related articles for article (PubMed ID: 24556643)
21. [Establishment and characterization of dual-color fluorescence nude mouse models of glioma].
Zhang J; Lu Z; Fei X; Dai X; Wu J; Wan Y; Wang Z; Wang A; Dong J; Lan Q; Huang Q
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):97-102. PubMed ID: 24796456
[TBL] [Abstract][Full Text] [Related]
22. Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.
Groblewska M; Mroczko B
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200145
[TBL] [Abstract][Full Text] [Related]
23. Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy.
Jain A; Lai JC; Bhushan A
Anticancer Drugs; 2015 Mar; 26(3):323-30. PubMed ID: 25501542
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
25. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and antiangiogenic therapy for malignant gliomas.
Takano S; Kamiyama H; Tsuboi K; Matsumura A
Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Strieth S; Eichhorn ME; Sutter A; Jonczyk A; Berghaus A; Dellian M
Int J Cancer; 2006 Jul; 119(2):423-31. PubMed ID: 16477628
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
29. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse.
Vajkoczy P; Schilling L; Ullrich A; Schmiedek P; Menger MD
J Cereb Blood Flow Metab; 1998 May; 18(5):510-20. PubMed ID: 9591843
[TBL] [Abstract][Full Text] [Related]
30. Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D ΔR2-μMRA.
Lin CY; Siow TY; Lin MH; Hsu YH; Tung YY; Jang T; Recht L; Chang C
Angiogenesis; 2013 Oct; 16(4):785-93. PubMed ID: 23736837
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.
Bexell D; Gunnarsson S; Tormin A; Darabi A; Gisselsson D; Roybon L; Scheding S; Bengzon J
Mol Ther; 2009 Jan; 17(1):183-90. PubMed ID: 18985030
[TBL] [Abstract][Full Text] [Related]
32. How does antiangiogenic therapy affect brain tumor response to radiation?
Weichselbaum RR
Nat Clin Pract Oncol; 2005 May; 2(5):232-3. PubMed ID: 16264953
[No Abstract] [Full Text] [Related]
33. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors.
Udani V; Santarelli J; Yung Y; Cheshier S; Andrews A; Kasad Z; Tse V
Neurol Res; 2005 Dec; 27(8):801-6. PubMed ID: 16354539
[TBL] [Abstract][Full Text] [Related]
35. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis.
Ho IA; Toh HC; Ng WH; Teo YL; Guo CM; Hui KM; Lam PY
Stem Cells; 2013 Jan; 31(1):146-55. PubMed ID: 23034897
[TBL] [Abstract][Full Text] [Related]
36. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.
Czabanka M; Parmaksiz G; Bayerl SH; Nieminen M; Trachsel E; Menssen HD; Erber R; Neri D; Vajkoczy P
Eur J Cancer; 2011 May; 47(8):1276-84. PubMed ID: 21396810
[TBL] [Abstract][Full Text] [Related]
37. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.
Aghi M; Cohen KS; Klein RJ; Scadden DT; Chiocca EA
Cancer Res; 2006 Sep; 66(18):9054-64. PubMed ID: 16982747
[TBL] [Abstract][Full Text] [Related]
38. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
39. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
